Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Recurrence 1Neoplasms, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Dexamethasone 2Calcium Dobesilate 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2venetoclax 1ixazomib 1daratumumab 1belantamab mafodotin 1X-Rays 1Stem Cell Transplantation 1Phantoms, Imaging 1Melphalan 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × belantamab mafodotin × 30 days × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡